BDX logo

Becton, Dickinson and Company Stock Price

NYSE:BDX Community·US$55.2b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 38 Fair Values set on narratives written by author

BDX Share Price Performance

US$192.72
-32.76 (-14.53%)
US$201.49
Fair Value
US$192.72
-32.76 (-14.53%)
6.7% undervalued intrinsic discount
US$206.58
Fair Value
Price US$192.72
AnalystConsensusTarget US$206.58

BDX Community Narratives

AnalystConsensusTarget·
Fair Value US$201.49 4.4% undervalued intrinsic discount

Advanced Diagnostics And Tissue Regeneration Will Expand Decentralized Healthcare

0users have liked this narrative
0users have commented on this narrative
19users have followed this narrative

Updated Narratives

BDX logo

Advanced Diagnostics And Tissue Regeneration Will Expand Decentralized Healthcare

Fair Value: US$201.49 4.4% undervalued intrinsic discount
19 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Established dividend payer and fair value.

2 Risks
3 Rewards

Becton, Dickinson and Company Key Details

US$21.8b

Revenue

US$11.8b

Cost of Revenue

US$10.0b

Gross Profit

US$8.3b

Other Expenses

US$1.7b

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
5.85
45.89%
7.68%
75.5%
View Full Analysis

About BDX

Founded
1897
Employees
70000
CEO
Thomas Polen
WebsiteView website
www.bd.com

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Recent BDX News & Updates

Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings

Nov 16
Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings

Recent updates

No updates